Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Baba, Fumiya ^a,b   Shibamoto, Yuta ^a   Ogino, Hiroyuki ^a   Murata, Rumi ^a   Sugie, Chikao ^a   Iwata, Hiromitsu ^a   Otsuka, Shinya ^a   Kosaki, Katsura ^a   Nagai, Aiko ^a   Murai, Taro ^a   Miyakawa, Akifumi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b CHUKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATELECTASIS; CANCER CONTROL; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; EDEMA; EFFUSION; ESOPHAGITIS; FEMALE; HEART MUSCLE INJURY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PLEURA EFFUSION; PNEUMOTHORAX; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RIB FRACTURE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; TUMOR VOLUME; CLINICAL TRIAL; KAPLAN MEIER METHOD; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RADIOSURGERY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOSURGERY; TREATMENT OUTCOME;

EID: 77957801213     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-81     Document Type: Article

References (27)

1. Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, Wong JR, Kusano S. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small-cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001, 51:666-670.
2. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, MIzowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, HIraoka M. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427-1431. 10.1016/j.ijrobp.2005.05.034, 16169670.
3. Onimaru R, Fujino M, Yamazaki K, Onodera Y, Taguchi H, Katoh N, Hommura F, Oizumi S, Nishimura M, Shirato H. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2009, 70:374-381.
4. Koto M, Takai Y, Ogawa Y, Matsushita H, Kateda K, Takahashi C, Britton KR, Jingu K, Takai K, Mitsuya M, Nemoto K, Yamada S. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007, 85:429-434. 10.1016/j.radonc.2007.10.017, 18022720.
5. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296. 10.1200/JCO.2008.21.5681, 19414667.
6. Takeda A, Sanuki N, Kunieda E, Ohashi T, Oku Y, Takeda T, Shigematsu N, Kubo A. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009, 73:442-448.
7. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, Timmerman R. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009, 75:677-682.
8. Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, Mizowaki T, Yano S, Hiraoka M. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008, 72:398-403.
9. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584. 10.1200/JCO.2008.19.6386, 19255320.
10. Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, Onishi H, Shirato H. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D conformal external beam radiotherapy group. Int J Radiat Oncol Biol Phys 2009, 75:343-347.
11. Baba F, Shibamoto Y, Tomita N, Ikeya-Hashizume C, Oda K, Ayakawa S, Ogino H, Sugie C. Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results. Radiat Oncol 2009, 4. article 15, 10.1186/1748-717X-4-15, 2694202, 19476628.
12. Iwata H, Shibamoto Y, Murata R, Tomita N, Ayakawa S, Ogino H, Ito M. Estimation of errors associated with use of linear-quadratic formalism for evaluation of biologic equivalence between single and hypofractionated radiation doses: an in vitro study. Int J Radiat Oncol Biol Phys 2009, 75:482-488.
13. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839. 10.1200/JCO.2006.07.5937, 17050868.
14. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2(Suppl 3):S94-100. 10.1097/JTO.0b013e318074de34, 17603311.
15. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 52:382-389.
16. Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003, 41:1-11. 10.1016/S0169-5002(03)00152-1, 12826306.
17. Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 1986, 77:908-915.
18. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076. 10.1001/jama.2010.261, 2907644, 20233825.
19. Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, Richter A, Wilbert J, Flentje M. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009, 74:47-54.
20. Haedinger U, Krieger T, Flentje M, Wulf J. Influence of calculation model on dose distribution in stereotactic radiotherapy for pulmonary targets. Int J Radiat Oncol Biol Phys 2005, 61:239-249.
21. Takeda A, Kunieda E, Sanuki N, Ohashi T, Oku Y, Sudo Y, Iwashita H, Ooka Y, Aoki Y, Shigematsu N, Kubo A. Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Int J Radiat Oncol Biol Phys 2009, 74:363-369.
22. Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Onimaru R, van den Heuvel MM, Belderbos J, Lebesque JV, Sonke JJ. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 2009, 91:307-313. 10.1016/j.radonc.2009.02.003, 19321217.
23. Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, Mueller G, Flentje M. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 2010,
24. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45:323-329.
25. Kwa SL, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G, Oetzel D, Spahn U, Graham MV, Drzymala RE, Purdy JA, Lichter AS, Martel MK, Ten Haken RK. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998, 42:1-9.
26. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010, 94:1-11. 10.1016/j.radonc.2009.12.008, 20074823.
27. Chen Y, Guo W, Lu Y, Zou B. Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy. Radiother Oncol 2008, 88:351-358. 10.1016/j.radonc.2008.07.013, 18722684.